Trend of extracorporeal membrane oxygenation support in patients with acute respiratory distress syndrome in South Korea.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 03 2022
28 03 2022
Historique:
received:
01
09
2021
accepted:
18
02
2022
entrez:
29
3
2022
pubmed:
30
3
2022
medline:
5
4
2022
Statut:
epublish
Résumé
We examined and compared the clinical characteristics of acute respiratory distress syndrome (ARDS) patients who received and did not receive extracorporeal membrane oxygenation (ECMO) support. The national health insurance database of South Korea was used to obtain real-world data. All adult patients admitted to intensive care units for ARDS treatment between 1 January 2014 and 31 December 2019 were included in this study. Of the 10,173 patients with ARDS included in the analysis, 740 (7.3%) received ECMO support for a mean duration of 1.6 days (standard deviation [SD]: 2.8 days) and were assigned to the ECMO group. The ECMO group had a significantly lower mean age at 57.0 years (SD: 15.7 years) than the non-ECMO group (71.8 Â years [SD: 15.1 Â years], P < 0.001). In multivariable logistic regression, a 1-year increase in age was associated with a 5% lower prevalence of ECMO support. The annual case volume was classified into four groups by quartile ratio (Q1 [lowest], Q2, Q3, and Q4 [highest]), and Q2, Q3, and Q4 groups showed a higher prevalence of ECMO support than the Q1 group. ECMO support was also performed more frequently in high case volume centers than in low case volume centers for ARDS patients.
Identifiants
pubmed: 35347185
doi: 10.1038/s41598-022-09230-9
pii: 10.1038/s41598-022-09230-9
pmc: PMC8959791
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5225Informations de copyright
© 2022. The Author(s).
Références
Crit Care Med. 2018 Jan;46(1):e33-e40
pubmed: 29095203
J Clin Med. 2021 Oct 21;10(21):
pubmed: 34768359
PLoS One. 2016 Jun 23;11(6):e0158061
pubmed: 27336170
Lancet Respir Med. 2019 Feb;7(2):163-172
pubmed: 30642776
Circulation. 2019 Jan 22;139(4):428-430
pubmed: 30664369
Eur J Cardiothorac Surg. 2010 Feb;37(2):339-42
pubmed: 19699650
Appl Health Econ Health Policy. 2015 Aug;13(4):341-57
pubmed: 25894740
Am J Respir Crit Care Med. 2020 Aug 1;202(3):460-463
pubmed: 32543208
Ann Thorac Surg. 2017 Jul;104(1):62-69
pubmed: 28131429
Pharmacoecon Open. 2021 Dec;5(4):613-623
pubmed: 34060061
ASAIO J. 2014 Jul-Aug;60(4):385-90
pubmed: 24830799
Intensive Care Med. 2012 Mar;38(3):395-403
pubmed: 22323077
Intensive Care Med. 2020 Nov;46(11):2048-2057
pubmed: 33021684
Health Policy Plan. 2009 Jan;24(1):63-71
pubmed: 19004861
Lancet. 2020 Oct 10;396(10257):1071-1078
pubmed: 32987008
Am J Respir Crit Care Med. 2015 Apr 15;191(8):894-901
pubmed: 25695688
BMC Infect Dis. 2021 Jun 4;21(1):525
pubmed: 34088271
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Ann Am Thorac Soc. 2020 Jul;17(7):800-803
pubmed: 32292052
J Thorac Dis. 2015 Jul;7(7):E166-76
pubmed: 26380745
Lancet Respir Med. 2020 Nov;8(11):1121-1131
pubmed: 32798468
Ann Thorac Surg. 2007 Jan;83(1):140-5
pubmed: 17184647
J Thorac Dis. 2018 Mar;10(3):1406-1417
pubmed: 29707290
Chest. 2014 Apr;145(4):876-882
pubmed: 24687709